Cargando…
Development of Glucose Transporter (GLUT) Inhibitors
The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and gluco...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217229/ https://www.ncbi.nlm.nih.gov/pubmed/32421048 http://dx.doi.org/10.1002/ejoc.201901353 |
_version_ | 1783532575675908096 |
---|---|
author | Reckzeh, Elena S. Waldmann, Herbert |
author_facet | Reckzeh, Elena S. Waldmann, Herbert |
author_sort | Reckzeh, Elena S. |
collection | PubMed |
description | The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and glucose metabolism and an increased glucose demand. Thus, targeting glucose uptake and metabolism may open up novel opportunities for the discovery of compounds that differentiate between normal and malignant cells. This review discusses the different chemical approaches to the development of novel inhibitors of glucose uptake through facilitative glucose transporters (GLUTs), and focusses on the most advanced and potent inhibitor classes known to date. GLUT inhibitors may find application not only in the treatment of cancer, but also of other proliferative diseases that exhibit glucose addiction. |
format | Online Article Text |
id | pubmed-7217229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72172292020-05-13 Development of Glucose Transporter (GLUT) Inhibitors Reckzeh, Elena S. Waldmann, Herbert European J Org Chem Minireviews The discovery of novel compound classes endowed with biological activity is at the heart of chemical biology and medicinal chemistry research. This enables novel biological insights and inspires new approaches to the treatment of diseases. Cancer cells frequently exhibit altered glycolysis and glucose metabolism and an increased glucose demand. Thus, targeting glucose uptake and metabolism may open up novel opportunities for the discovery of compounds that differentiate between normal and malignant cells. This review discusses the different chemical approaches to the development of novel inhibitors of glucose uptake through facilitative glucose transporters (GLUTs), and focusses on the most advanced and potent inhibitor classes known to date. GLUT inhibitors may find application not only in the treatment of cancer, but also of other proliferative diseases that exhibit glucose addiction. John Wiley and Sons Inc. 2019-11-28 2020-05-03 /pmc/articles/PMC7217229/ /pubmed/32421048 http://dx.doi.org/10.1002/ejoc.201901353 Text en © 2019 The Authors. Published by Wiley‐VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Minireviews Reckzeh, Elena S. Waldmann, Herbert Development of Glucose Transporter (GLUT) Inhibitors |
title | Development of Glucose Transporter (GLUT) Inhibitors |
title_full | Development of Glucose Transporter (GLUT) Inhibitors |
title_fullStr | Development of Glucose Transporter (GLUT) Inhibitors |
title_full_unstemmed | Development of Glucose Transporter (GLUT) Inhibitors |
title_short | Development of Glucose Transporter (GLUT) Inhibitors |
title_sort | development of glucose transporter (glut) inhibitors |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217229/ https://www.ncbi.nlm.nih.gov/pubmed/32421048 http://dx.doi.org/10.1002/ejoc.201901353 |
work_keys_str_mv | AT reckzehelenas developmentofglucosetransporterglutinhibitors AT waldmannherbert developmentofglucosetransporterglutinhibitors |